Navigation Links
Survival Data Available From Erbitux Study in First-Line Treatment,of Advanced Head and Neck Cancer

-- First large, randomized Phase III study of ERBITUX with chemotherapy in recurrent and/or metastatic head and neck cancer meets primary endpoint of improving overall survival --

NEW YORK, April 04, 2007 /PRNewswire-FirstCall/ -- ImClone Systems Incorporated and Bristol-Myers Squibb Company announced today that a first line Phase III study of ERBITUX(R) (Cetuximab) combined with platinum-based chemotherapy met the primary endpoint of increasing overall survival in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN). The randomized, multi-center study, known as EXTREME, studied more than 400 patients treated with ERBITUX in combination either with cisplatin plus 5-fluorouracil (5-FU) or carboplatin plus 5-FU, compared to patients treated with cisplatin plus 5-FU or carboplatin plus 5-FU alone.

"We are excited by the results of this study, as it is the first large, randomized clinical trial to examine the impact of ERBITUX treatment in combination with platinum-based chemotherapy on overall survival in metastatic head and neck cancer," said Eric Rowinsky, M.D., Chief Medical Officer and Senior Vice President of ImClone Systems. "ERBITUX has already demonstrated improved survival when combined with radiation in locoregionally advanced head and neck cancer."

"When ERBITUX was approved for head and neck cancer, it was not only hailed as the first new treatment for the disease in 45 years, but it was also the first drug approved to show a survival benefit in this population. Just one year later, this study adds to the growing body of clinical evidence with ERBITUX in these patients," said Martin Birkhofer, M.D., Vice President, Oncology Global Medical Affairs, Bristol-Myers Squibb.

Results from this study have been submitted for presentation at the 2007 American Society of Clinical Oncology Annual Meeting in Chicago, June. \

About Head and Neck C
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
2. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
3. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
4. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
5. Velcade (bortezomib) for Injection Survival Data in Front-Line Multiple Myeloma Patients to be Featured at 11th International Myeloma Workshop
6. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
7. Anastrozole (Arimidex) Improves Overall Survival in Postmenopausal Women with Early Breast Cancer Receiving Treatment with Tamoxifen
8. Ivivis PEMF Technology Significantly Improves Neuron Survival in Parkinsons Disease Model, Study Finds
9. Synta Presents Results for STA-4783 in Metastatic Melanoma Showing Improvement in Overall Survival
10. Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival
11. Updated Study Results Reinforce Survival Benefit of Taxotere (Docetaxel) for Men with Advanced, Hormone-Resistant Prostate Cancer
Post Your Comments:
(Date:1/15/2014)... , Jan. 15, 2014  In an unprecedented effort to curb the ... ambulances and other transport vehicles, an advanced and portable UV germicidal ... for the first time. In order to prevent ... deadly pathogens, West Palm Beach Fire Rescue ...
(Date:1/15/2014)... TORONTO , Jan. 15, 2014  According to ... medical technology market intelligence, the United ... occlusion (TEO) device markets will expand moderately through ... fastest-growing segments. In particular, increasing interest in drug-eluting ...
(Date:1/15/2014)... , Jan. 15, 2014 ... research report is available in its ... Markets and Technologies for Advanced Drug ... of Administration ...
Breaking Medicine Technology:Superbugs No Longer Ride In Rescue Vehicles 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16
(Date:4/17/2014)... The presence of chronic inflammation in benign ... prostate cancer, and this association was found even ... according to a study published in Cancer ... the American Association for Cancer Research. , An ... participants of the placebo arm of the Prostate ...
(Date:4/17/2014)... to a study published today in PLOS Pathogens ... where malaria is common can mount an immune response ... to avoid repeated bouts of high fever and illness ... their bloodstream. The findings may help researchers develop future ... the malaria parasite. , Each year, approximately 200 million ...
(Date:4/17/2014)... Bonheur Children,s Hospital Pediatrician-in-Chief Jon McCullers, MD, was ... April issue of Nature Reviews Microbiology , ... Dr. McCullers, a world-renowned infectious disease specialist, and ... University of Tennessee Health Science Center, analyzed the ... 1957 and 1968 pandemics, as well as more ...
(Date:4/17/2014)... The cause of neuronal death in Parkinson,s disease is ... may be mistaken for foreign invaders and killed by ... autoimmune diseases like type I diabetes, celiac disease, and ... published April 16, 2014, in Nature Communications . ... in Parkinson,s disease; but if true, it could lead ...
(Date:4/17/2014)... team led by researchers at UC Davis has shown ... key role in cell division, also boosts the mitochondrial ... time the complex has been shown to perform both ... excellent target to control cellular energy production, potentially advancing ... online today in the journal Developmental Cell . ...
Breaking Medicine News(10 mins):Health News:Chronic inflammation may be linked to aggressive prostate cancer 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 3Health News:Study sheds light on how the immune system protects children from malaria 2Health News:Is Parkinson's an autoimmune disease? 2Health News:Dual role: Key cell division proteins also power up mitochondria 2
... ALTO, Calif., April 29 Varian Medical Systems (NYSE: ... continuing operations of $0.64 per diluted share in the ... from continuing operations of $0.57 per diluted share in ... instruments operation, net earnings per diluted share in the ...
... Varian, Inc. (NasdaqGS: VARI) today reported second quarter fiscal ... 17.2% from the second quarter of fiscal year 2008.Non-GAAP ... of 2009 were $0.55 (including $0.05 of share-based compensation ... $0.07 of share-based compensation expense) in the second quarter ...
... juice could slow prostate cancer , , WEDNESDAY, April 29 ... a citrus flavor, might help ward off painful calcium ... citrate, which is known to inhibit calcium formation, according ... be presented Sunday at the American Urological Association annual ...
... years, report warns , , WEDNESDAY, April 29 (HealthDay News) -- ... of new cancers over the next two decades, driven by ... new report predicts. , Rates of new cancer diagnosis ... generally and by 67 percent among people aged 65 or ...
... INDIANAPOLIS , April 29 /PRNewswire/ ... a good start. WellPoint is pleased that the ... underlying quality and cost issues within our health care ... programs and services private plans have pioneered. We also ...
... Nancy Pelosi spoke on the House floor this morning in strong ... The resolution passed the House by a vote of 233 to ... today. It does not require the signature of the President. Below ... indeed an honor to call Mr. Spratt a colleague. We say ...
Cached Medicine News:Health News:Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2009 2Health News:Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2009 3Health News:Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2009 4Health News:Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2009 5Health News:Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2009 6Health News:Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2009 7Health News:Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2009 8Health News:Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2009 9Health News:Varian, Inc. Reports Second Quarter 2009 Results 2Health News:Varian, Inc. Reports Second Quarter 2009 Results 3Health News:Varian, Inc. Reports Second Quarter 2009 Results 4Health News:Varian, Inc. Reports Second Quarter 2009 Results 5Health News:Varian, Inc. Reports Second Quarter 2009 Results 6Health News:Varian, Inc. Reports Second Quarter 2009 Results 7Health News:Varian, Inc. Reports Second Quarter 2009 Results 8Health News:Varian, Inc. Reports Second Quarter 2009 Results 9Health News:Varian, Inc. Reports Second Quarter 2009 Results 10Health News:Varian, Inc. Reports Second Quarter 2009 Results 11Health News:Varian, Inc. Reports Second Quarter 2009 Results 12Health News:Varian, Inc. Reports Second Quarter 2009 Results 13Health News:Varian, Inc. Reports Second Quarter 2009 Results 14Health News:Varian, Inc. Reports Second Quarter 2009 Results 15Health News:Varian, Inc. Reports Second Quarter 2009 Results 16Health News:Varian, Inc. Reports Second Quarter 2009 Results 17Health News:Varian, Inc. Reports Second Quarter 2009 Results 18Health News:Varian, Inc. Reports Second Quarter 2009 Results 19Health News:Varian, Inc. Reports Second Quarter 2009 Results 20Health News:Varian, Inc. Reports Second Quarter 2009 Results 21Health News:Varian, Inc. Reports Second Quarter 2009 Results 22Health News:Varian, Inc. Reports Second Quarter 2009 Results 23Health News:Some Diet Sodas May Ward Off Kidney Stones 2Health News:Some Diet Sodas May Ward Off Kidney Stones 3Health News:Minorities to Bear Brunt of Rise in U.S. Cancer Cases 2Health News:Minorities to Bear Brunt of Rise in U.S. Cancer Cases 3Health News:Pelosi: Budget is a Blueprint for the Future 2
Curved to the Left 9# with 30 cm long silicone tubing with connector; 40mm overall length; in stainless steel...
... Cordis biopsy forceps are designed for endomyocardial biopsies. ... consist of a 3-pull ring handle, stainless steel ... thumb ring rotates to accommodate any position. ,A ... closed. The jaws are opened by moving the ...
4-Strand Basket Retriever was developed to facilitate recovery of foreign objects from within the neuro, peripheral, and cardiovasculature, the In-Time Retrieval Device features an integrated corewir...
... non-invasive, virtually pain-free alternative to conventional open ... indications. With Leksell Gamma Knife C the ... improves the ability to mould the radiation ... allows a more selective irradiation and thus ...
Medicine Products: